PULSE BIOSCIENCES, INC.

Note1. Description of the Business

Pulse Biosciences, Inc. is a novel ablation company committed to health innovation using its patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of asecond long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as a Nanosecond Pulsed-Field Ablation (“nsPFA”) energy when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. The Company developed its proprietary nPulse System, a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA energy to treat benign lesions of the skin and in parallel, designed a variety of applicators, or disposables, to explore the potential use of the nPulse platform in other medical specialties. Based on its preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided to focus its primary efforts on the use of nsPFA energy and the nPulse platform in the treatment of atrial fibrillation (“AF”), and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

The Company is incorporated in the State of Delaware. It is located in Hayward, California. The Company maintains its website at www.pulsebiosciences.com where general information about the Company is available.

Liquidity and Capital Resources

The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $529.6 million as of* September 30, 2026.As of September 30, 2026,the Company had cash, cash equivalents and marketable securities of $189.2 million. The Company believes that the existing financial resources are sufficient to continue operating activities for at leastone* year past the issuance date of these condensed consolidated financial statements.

The Company has historically financed its operations primarily through the sale of common stock and debt. To date, the Company has generated limited revenue from product sales and has incurred significant operating losses in each year since inception. The Company* may*continue to incur additional losses for the next several years.

While the Company has been able to raise multiple rounds of financing and sell shares pursuant to its at-the-market program, there can beno assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to raise sufficient capital when needed or generate sufficient cash flow from operations would impact the ability to pursue business strategies and could require the Company to delay, scale back or discontinueone or more product development programs, or other aspects of the Company’s business objectives.

Note2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s* December 31, 2025audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2025was derived from the audited consolidated financial statements as of that date but doesnot* include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form10-K for the year ended* December 31, 2025.The results of operations for thenine* months ended* September 30, 2026,arenot* necessarily indicative of the results to be expected for the entire year or any future periods.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries and intercompany balances and transactions have been eliminated in consolidation.

9

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but arenot limited to, accrued research and development expenses, the valuation and recognition of stock-based compensation, inventory valuation, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company invests in money market funds, U.S. treasury securities, and certificates of deposit. Deposits held with banks* mayexceed the amount of insurance provided on such deposits. The Company hasnot* experienced any losses since inception on such accounts or any credit losses with respect to its cash equivalents and investments and doesnot believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Fair Value of Financial Instruments

The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, athree-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

Level1 – Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.

Level2 – Observable inputs other than Level1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that arenot active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level3 – Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

Financial instruments carried at fair value include cash, cash equivalents and marketable securities. Financial instruments classified within Level2 of the fair value hierarchy are valued based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities arenot available, the Company relies on non-binding quotes from its investment managers, which are based on proprietary valuation models of independent pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments, or historical pricing trends of a security relative to its peers. The carrying amounts of accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity ofthree months or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value.

10

Marketable Securities

The Company’s marketable securities have been classified and accounted for as available-for-sale securities. Fixed income securities consist of U.S. treasury securities and certificates of deposit. The specific identification method is used to determine the cost basis of fixed income securities sold. These securities are recorded on the condensed consolidated balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive income or loss. The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense). All available-for-sale securities are considered available to support current operations and are classified as current assets. The Company presents any credit losses identified as an allowance rather than as a reduction in the amortized cost of the available-for-sale securities.

For available-for-sale debt securities in an unrealized loss position, the Companyfirst assesses whether it intends to sell, or it is more likely thannot that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value and recognized in other income (expense) in the condensed consolidated statements of operations. If neither criteria is met, the Company evaluates whether the decline in fair value is related to credit-related factors or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. Credit-related impairment losses, limited by the amount that the fair value is less than the amortized cost basis, are recorded through an allowance for credit losses in other income (expense).

Any unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit factors are recognized in accumulated other comprehensive income, net of tax as a separate component of stockholders’ equity, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on available-for-sale securities are included in other income (expense) in the condensed consolidated statements of operations.

For purposes of identifying and measuring credit-related impairments, the Company’s policy is to exclude applicable accrued interest from both the fair value and amortized cost basis of the related security. The Company has elected to write-off uncollectible accrued interest receivable balances in a timely manner, which is defined by the Company as when interest due becomes90 days delinquent. The accrued interest write-off will be recorded by reversing interest income. Accrued interest receivable is recorded to prepaid expenses and other current assets on the condensed consolidated balance sheets.

Accounts Receivable

Accounts receivable are recorded at invoice value, net of any allowance for credit losses. The allowance for credit losses is based on the Company’s assessment of the collectability of customer accounts. The Company’s expected loss allowance methodology for receivables considers factors such as historical collection experience, credit quality, age of the accounts receivable balances, and current economic conditions that* mayaffect a customer’s ability to pay. Any amounts deemed uncollectible are written off against the allowance for credit losses. There wasno allowance for credit losses as of September 30, 2026and December 31, 2025.*

Inventory

Inventory is stated at the lower of cost or net realizable value and based on standard costs approximating the purchase costs on afirst-in,first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost-basis of the Company’s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Additionally, the cost basis of the Company’s inventory doesnot include any fixed overhead costs associated with abnormally low utilization of its manufacturing facility.

During the year ended* December 31, 2025,the Company determined that inventory costs had future economic benefit subsequent to receiving FDA approval, and as such, it began to capitalize inventory for its limited market release of percutaneous electrodes for its Vybrance Percutaneous Electrode System. Prior to capitalizing inventory, all direct and indirect manufacturing costs were charged to research and development expenses in the period incurred or written off as excess and obsolete inventory in2022,* including previously manufactured consoles.

11

Property and Equipment

Property and Equipment is recorded at cost and depreciated using the straight-line method over their estimated useful lives, ranging from three tofive years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life. Upon the sale or retirement of property and equipment, the costs and related accumulated depreciation and amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operating expenses in the condensed consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.

Intangible Assets

The Company’s intangible assets consist of acquired patents and licenses, which are amortized over their estimated useful lives oftwelve years.

Impairment of Long-Lived Assets

The Company reviews long-lived assets, consisting of property and equipment and intangible assets, for impairment during each fiscal year or when events or changes in circumstances indicate the carrying value of these assets* mayexceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. During thethree* andnine months ended* September 30, 2026,the Company recognizedno impairment losses and an impairment loss of less than $0.1 million, respectively, related to an intangible asset. The Company concluded that the remaining long-lived assets didnot* have any indicators of impairment as of* September**30,* 2026. There wereno impairment losses recognized in the other periods presented.

Goodwill

The Company records goodwill when the consideration paid in a business acquisition exceeds the fair value of the net tangible assets and the identified intangible assets acquired. The Company reviews goodwill for impairment at the reporting unit level, of which there isone reportable unit, at least annually or whenever changes in circumstances indicate that the carrying value of the goodwill* may**not* be recoverable. To date, there has beenno impairment of goodwill.

Revenue from Contracts with Customers

The Company accounts for a contract with a customer when the rights and obligations of the parties are identifiable, the contract has commercial substance, and the collectability of the consideration to be received from the customer is considered probable. Contracts with customers are for the sale of the nPulse Vybrance System, which includes system components, software, and system accessories. Instruments and other accessories* mayalso be included with the system or may*be sold on a standalone basis. These products are considered performance obligations to the extent they are separately identifiable from other products in the contract and when the customer can either benefit from the product on its own or with other goods or services that are readily available to the customer.

The Company recognizes revenue at a point in time when it satisfies performance obligations by transferring control of promised goods to its customers. Transfer of control occurs based on shipping terms as contractually negotiated. The amount of revenue recognized is equal to the consideration to which the Company expects to be entitled in exchange for the promised goods. Though some products* maybe sold on a stand-alone basis, initial customer contracts will likely involve the bundling of products which will be delivered concurrently to the customer for a single price. The initial limited market release period will also include evaluation agreements with customers that allow either the Company or the customer to terminate the contract at any point without penalty. The termination right limits the effective contract term to the period for which the contract wasnot* terminated. The Company generally extends payment terms to customers after the Company performs a necessary credit evaluation to ensure future collectability of the outstanding balance. Payment generally occurs within a relatively short period of time after delivery of products.

The transaction price is the consideration to which the Company expects to be entitled in exchange for providing the promised goods to customers. Though most customer orders are for a fixed amount of consideration, the Company evaluates the possible impact of variable consideration in determining the transaction price, in particular the possibility of future returns. Sales agreements allow for a right of return only if the product doesnot conform to the agreed upon quality standards or if the product was shipped due to Company error. The Company anticipates such returns will be minimal and has madeno adjustments to the transaction price for any estimated returns. The transaction price is determined at contract execution and updated each quarter for any changes in circumstances (e.g., changes in estimated return amount).

The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes which are imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.

12

When there are multiple performance obligations present, the total transaction price shall be allocated to each of the performance obligations based upon the relative standalone selling price (“SSP”) of those performance obligations. The Company establishes SSPs based on multiple factors including prices charged by the Company for similar offerings, product-specific business objectives, and the estimated cost to provide the performance obligation.

Shipping and handling activities arenot considered to be a separate performance obligation. The Company has made an accounting policy election to account for shipping and handling activities as fulfillment activities when these activities occur after the customer obtains control of the product.

The Company has determined that certain promises in the multiple-element arrangements, such as installation, training, and certain ancillary products, are immaterial in the context of the contract and donot represent separate performance obligations to which transaction price is allocated.

The Company utilizes the practical expedient under ASC606 and doesnot disclose unsatisfied performance obligations for contracts as the contracts generally have an original duration of less thanone year. Additionally, the Company doesnot currently have significant contract assets or deferred revenue.

The Company doesnot incur contract origination costs.

Research and Development Expenses

Research and development expenses consist primarily of compensation expenses, fees paid to consultants and outside service providers and organizations (including university research institutes), costs associated with clinical trials, development prototypes and other expenses relating to the acquisition, design, development and testing of the Company’s product candidates, and certain facilities related costs. Research and development expenses incurred by the Company are expensed as incurred.

Accrued Research and Development Expenses

The Company accrues liabilities for estimated costs of research and development activities conducted by itsthird-party service providers, which include the conduct of preclinical and clinical studies. The estimated costs of research and development activities are recorded based upon the estimated amount of services provided butnot yet invoiced, and these costs are included in accrued liabilities on the condensed consolidated balance sheets and within research and development expense on the condensed consolidated statements of operations.

These costs are accrued based on factors such as estimates of the work completed and budget provided and in accordance with agreements established withthird-party service providers. Significant judgments and estimates are made in determining the accrued liabilities balance in each reporting period. Accrued liabilities are adjusted as actual costs become known. Changes in these estimates that result in material changes to the Company’s accruals could materially affect its financial condition and results of operations. There havenot been any material differences between accrued costs and actual costs incurred since the Company’s inception.

Patent Expenses

The Company is the owner of numerous domestic and foreign patents. Due to the significant uncertainty associated with the successful development ofone or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costsnot related to acquired patents, including patent-related legal fees, filing fees and other costs, including internally generated costs, are expensed as incurred. Patent expenses are included in selling, general and administrative expenses in the condensed consolidated statements of operations.

Stock-Based Compensation

The Company’s stock-based compensation programs include stock options, restricted stock units (RSUs), and an employee stock purchase program. The Company periodically issues stock options and RSUs to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. In general, stock options granted are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model or the Monte Carlo simulation model. The grant date fair value of RSUs is estimated based on the closing stock price of the Company’s common stock on the date of grant. The Company accounts for forfeitures as they occur. The Company has granted stock options with service-based, performance-based, market-based, and both market-based and performance-based vesting conditions and granted RSUs with service-based and performance-based vesting conditions.

13

For stock options with service-based and performance-based vesting conditions, the grant date fair value of each grant is determined using the Black-Scholes option pricing model which requires a number of assumptions. Each of these assumptions is subjective and generally requires significant judgment and estimation by management.

*Expected Term –The Company’s expected term represents the period that the Company’s stock awards are expected to be outstanding and is *determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).

*Expected Volatility –*The computation of expected volatility is based on a calculation using the historical volatility of the Company’s common stock.

*Risk-Free Interest Rate –The risk-free interest rate is based on the Treasury Constant Maturities as provided by the Federal Reserve in effect at the *time of grant for periods corresponding with the expected term of the option.

Expected Dividend –The Company has never paid dividends on its common stock and hasno plans to pay dividends on its common stock. Therefore,* *the Company used an expected dividend yield of zero.

Stock-based compensation expense for stock awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. For stock awards with performance-based vesting conditions, the Company doesnot recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. The analysis to determine such probability involves estimates and judgements from management related to certain financial measures and achievements of strategic and operational milestones, which involve inherent risk and uncertainty regarding the future outcomes of the milestones. If actual results arenot consistent with the Company’s estimates or assumptions, the Company* may*be exposed to changes in stock-based compensation expense that could be material.

For stock awards with market-based vesting conditions, the conditions relate to the achievement of certain market capitalization targets of the Company. Using a Monte Carlo simulation model, the Company estimated the fair value of the market-based awards on the grant date or modification date, with the associated stock-based compensation expense recognized over the requisite service period. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the Company will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.

For stock awards with both market-based and performance-based vesting conditions, the conditions relate to both the achievement of certain market capitalization targets of the Company, as well as the achievement of certain revenue and/or margin metrics. Using a Monte Carlo simulation model, the Company estimates the fair value of the market-based options on the grant date, along with a derived service period. Compensation expense for the awards is recognized over the requisite service period, which is the longer of the service period derived from the Monte Carlo simulation model or the implicit service period (the period when the performance condition is expected to be met). Compensation expense is recognized only once it becomes probable that the associated performance condition will be achieved and the employee is expected to render the requisite service. Once these criteria are met, the Company will recognize expense using the accelerated attribution method over the requisite service period. If, at any point, the performance condition isno longer probable of being achieved or the employee isno longer expected to complete the requisite service period, any previously recognized expense will be reversed. Additionally, if both the market and performance conditions are satisfied before the end of the requisite service period, any remaining unrecognized expense will be recognized immediately, provided that the employee is still providing service.

The Monte Carlo simulation models require the Company to make assumptions and judgements about the variables used in the calculations including the expected volatility, the risk-free interest rate, expected dividend yield, and the expected term. The assumptions used in the option-pricing model represent management’s best estimates. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.

14

Income Taxes

The Company accounts for income taxes using the liability method, whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance when it is more likely thannot that some portion, or all of the Company’s deferred tax assets willnot be realized.

The Company accounts for income tax contingencies using a benefit recognition model. If it considers that a tax position is more likely thannot to be sustained upon audit, based solely on the technical merits of the position, it recognizes the benefit. The Company measures the benefit by determining the amount that is greater than50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information. The Company is subject to taxation in the United States federal jurisdiction, and various state jurisdictions. The net operating loss and research and development credit carryforwards that are available for utilization in future years* maybe subject to examination by federal and state tax authorities. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. As of September 30, 2026and December 31, 2025,*there wereno significant accruals for interest related to unrecognized tax benefits or tax penalties.

Comprehensive Loss

Comprehensive loss represents the net loss for the period and other comprehensive loss. Other comprehensive loss reflects certain gains and losses that are recorded as a component of stockholders’ equity and arenot reflected in the condensed consolidated statements of operations. The Company’s other comprehensive loss consists of changes in unrealized gains and losses on available-for-sale securities.

Net Loss Per Share

The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In* July 2025,the FASB issued ASU2025*-05, Financial Instruments—Credit Losses (Topic326*): Measurement of Credit Losses for Accounts Receivable and Contract Assets,which provides a practical expedient for entities to measure expected credit losses on current accounts receivable and current contract assets within the scope of ASC606,* Revenue from Contracts with Customers. The practical expedient assumes that current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The guidance is effective for interim and annual reporting periods beginning after* December 15, 2025.The Company adopted this guidance effective January 1, 2026.The adoption didnot* have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

Recent Accounting Pronouncements Not Yet Adopted

In* November 2024,the FASB issued ASU2024*-03, Disaggregation of Income Statement Expenses, which aims to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for the Company's annual periods beginning in2027 and interim periods beginning in thefirst quarter of fiscal year2028. The Company is currently evaluating the impact of the new guidance on our condensed consolidated financial statements and related disclosures.

15

Note3. Fair Value Measurement and Marketable Securities

The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company’s financial assets, which consist of cash equivalents and marketable securities measured and recognized at fair value (in thousands):

The Company measures the fair value of money market funds and U.S. treasury securities on quoted prices in active markets for identical asset or liabilities. The Level2 asset includes a certificate of deposit and is valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data.

The Company evaluates transfers between levels at the end of each reporting period. There wereno transfers between Levels1, 2, and3 during thethree andnine months ended* September 30, 2026and2025.* As of* September 30, 2026and December 31, 2025,there wereno financial instruments classified as Level3* and there wereno available-for-sale securities held as of* December 31, 2025.*

The following table summarizes the available-for-sale securities in an unrealized loss position for which an allowance for credit losses hasnot been recorded as of* September 30, 2026,*aggregated by major security type and length of time in a continuous unrealized loss position:

As of* September 30, 2026,the Company held 2 debt securities with an unrealized loss position. The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions andnot* to a credit loss or other factors. Additionally, the Company doesnot intend to sell the securities in an unrealized loss position and doesnot expect it will be required to sell the securities before recovery of the unamortized cost basis. As of* September 30, 2026,an allowance for credit losses hasnot been recognized. Given the Company's intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, it doesnot* consider these marketable securities impaired as of* September 30, 2026.*

There wereno realized gains or losses on marketable securities for thethree andnine months ended* September 30, 2026and2025.* Interest on cash equivalents and marketable securities is included in interest income. As of* September 30, 2026and December 31, 2025,*the Company had accrued interest receivable of $0.2 million and $0.3 million, respectively, which was included inprepaid expenses and other current assets on the condensed consolidated balance sheets.

16

As of* September 30, 2026and December 31, 2025,*the Company’s cash equivalents and marketable securities had contractual maturities of less thanone year.

Note4. Accrued Liabilities

In* March 2026,the Company announced a strategic and organizational realignment to prioritize and accelerate the development of its nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation (the“2026* Realignment”). In connection with the2026 Realignment, the Company recognized severance andone-time termination expenses of $0.6 million, with $0.5 million in payments remitted as of* September 30, 2026.*

Accrued liabilities consisted of the following (in thousands):

Note5. Stockholders' Equity

Preferred Stock

The Company has authorized a total of 50,000,000 shares of preferred stock, par value $0.001 per share, none of which were outstanding as of* September 30, 2026and December 31, 2025.*The Company’s Board of Directors (the “Board”) has the authority to issue preferred stock and to determine the rights, preferences, privileges, and restrictions, including voting rights, without any further vote or action by the Company’s stockholders.

Common Stock

The Company has authorized a total of 500,000,000 shares of common stock, par value $0.001 per share.

At-The-Market Stock Offerings

The Company entered into the following sales agreements with sales agents to issue and sell shares of its common stock under at-the-market offering programs (the “ATM Programs”) during thenine months ended* September 30, 2026 (*in thousands):

The following table summarizes shares of common stock issued and sold by the Company, and net proceeds, after deducting commissions and offering costs, under the ATM Programs (in thousands, except shares):

17

2024 Rights Offering and Subscription Rights

In2024, the Company executed a rights offering (the*“2024* Rights Offering”), whereby the Company distributed non-transferable subscription rights to purchase up to an aggregate ofsix million units (the*“2024* Units”) with an aggregate offering value of up to $60 million atno charge to all holders of the Company's common stock. The2024 Rights Offering resulted in the sale ofsix million 2024 Units, at a price of $10.00 per2024 Unit. Each2024 Unit consisted ofone share of the Company’s common stock, par value $0.001 per share, andtwo warrants, each being a warrant to purchaseone-half ofone share of common stock. The common stock and warrants comprising the2024 Units separated upon the closing of the2024 Rights Offering and were issued individually. A total of 5,999,998 shares of common stock and warrants to acquire up to approximately an additionalsix million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the2024 Rights Offering of $60 million. See2024 Rights Offering Warrants below for additional details of the warrants. Robert W. Duggan, the Company’s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the2024 Rights Offering.

Common Stock Warrants

2024 Rights Offering Warrants

In connection with the2024 Rights Offering, the Company issued2024 Rights Offering Warrants to purchase a total of 5,999,999 shares of its common stock at an exercise price of $11.00 per whole share, which equaled 110% of the subscription price for the Units. The aggregate number of shares of the Company’s common stock issuable upon the exercise of each set of warrants included in a given subscription for Units was rounded up to the nearest whole share. Warrants were exercisable immediately and expire on thefifth anniversary of the closing of the2024 Rights Offering. The warrants issued in the rights offering were redeemable by the Company for $0.01 per warrant, onnot less thanthirty days’ written notice, if the volume-weighted average price (“VWAP”) of the Company’s common stock equaled or exceeded 150% of the exercise price, or $16.50, fortwenty consecutive days forone-half of the warrants while the other half of the warrants required the VWAP of the Company’s common stock to equal or exceed 200% of the exercise price, or $22.00, fortwenty consecutive trading days.

In* February 2025,the Company redeemed thefirst* tranche of common stock warrants, pursuant to the 150% redemption feature, totaling 36,442 warrants, which would have entitled the holders to purchase up to 18,221 shares of common stock. In* July 2026,the Company redeemed thesecond* tranche of common stock warrants, pursuant to the 200% redemption feature, totaling 50,607 warrants, which would have entitled the holders to purchase up to 25,303 shares of common stock. As of* September 30, 2026,there wereno outstanding2024* Rights Offering Warrants.

For thenine months ended* September 30, 2026and2025,* the Company received gross proceeds of $2.0 million and $14.1 million, respectively, from exercises of the2024 Rights Offering Warrants. Cumulatively, as of* September 30, 2026,the Company has received total gross proceeds of $65.5 million from exercises of the2024* Rights Offering Warrants.

Note6. Stock-Based Compensation

2017 Equity Incentive Plan

In* May 2017,the Company’s Board of Directors (the “Board”) adopted, and the Company’s stockholders approved, the Company’s2017* Equity Incentive Plan (the*“2017* Plan”).

The2017 Plan has a 10-year term, and provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company.

18

Subject to an annual evergreen increase and adjustment in the case of certain capitalization events, the Company initially reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to awards under the2017 Plan. In addition, shares remaining available under the Company’s2015 Equity Incentive Plan, as amended (the*“2015* Plan”), and shares reserved butnot issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the2017 Plan. The2017 Plan is administered by the Compensation Committee of the Board. The number of shares of the Company’s common stock available for issuance under the2017 Plan also include an annual increase on thefirst day of each fiscal year, equal to the least of (i)1,200,000 shares, (ii)4% of the Company’s common stock outstanding at* December 31of the immediately preceding year, or (iii) such number of shares as determined by the Board. As a result of this provision, an additional 1,200,000 shares became available for issuance under the2017* Plan on* January 1, 2026.As of September 30, 2026,3,180,347 shares of common stock remained available for issuance under the2017* Plan.

2017 Inducement Equity Incentive Plan

In* November 2017,the Board adopted the2017* Inducement Equity Incentive Plan (the “Inducement Plan”) without stockholder approval and initially reserved 1,000,000 shares of the Company’s common stock for insurance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan has a 10-year term and provides for the grant of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the2017 Plan, including with respect to treatment of equity awards in the event of a “merger” or “change in control” as defined under the Inducement Plan. Options issued under the Inducement Plan* mayhave a term up toten years and have variable vesting provisions. New hire grants generally vest 25% per year starting upon thefirst anniversary of the grant. Equity-based awards issued under the Inducement Plan are only issuable to individualsnot* previously engaged as employees or non-employee directors of the Company prior to the Inducement Plan’s adoption date. As of* September 30, 2026,*1,591,659 shares of common stock were available for issuance under the Inducement Plan.

2017 Employee Stock Purchase Plan

In* May 2017,the Board adopted, and the Company’s stockholders approved, the Company’s2017* Employee Stock Purchase Plan (the*“2017* ESPP*”*).

The2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the2017 ESPP. Pursuant to the2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i)450,000 shares, (ii)1.5% of the Company’s common stock outstanding as of* December 31of the immediately preceding year, or (iii) such number of shares as determined by the Board. As a result of this provision, an additional 450,000 shares became available for issuance under the2017* ESPP on* January 1, 2026.As of September 30, 2026,1,240,070 shares of common stock were available for issuance under the2017* ESPP.

Equity Awards

The Company has granted stock options with service-based, performance-based, market-based, and both market-based and performance-based vesting conditions and has granted RSUs with service-based and performance-based vesting conditions. The Company grants service-based options and RSUs which vest and become exercisable, subject to the individual’s continued employment or service through the applicable vesting date. Service-based options and RSUs can have various vesting schedules, the most common vest schedules are for new hire stock option grants, which generally vest 25% per year starting upon thefirst anniversary of hire.

Performance-based stock options and RSUs granted to certain Company executives, employees and non-employees contain performance conditions related to financial measures and achievements of strategic and operational milestones. The options and RSUs will vest and become exercisable once the specific performance condition is fulfilled.

Market-based stock options granted to certain Company executives and other employees contain market conditions related to achievement of market capitalization targets. The options will vest and become exercisable once the specific market capitalization target is fulfilled.

19

Both market-based and performance-based stock options granted to certain Company executives contain market conditions related to the achievement of market capitalization targets as well as the achievement of revenue and/or margin metrics. The options will vest and become exercisable once both the specific market capitalization targets as well as the specific revenue and/or margin targets are fulfilled.

Stock Options

A summary of stock option activity for thenine months ended* September 30, 2026*is as follows:

The aggregate intrinsic value of stock options exercised was $23.9 million and $6.2 million for thenine months ended* September 30, 2026and2025,* respectively. Intrinsic values of options exercised are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock on the date of exercise. Intrinsic values of options outstanding are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock as of the reporting date.

The weighted-average grant date fair value of options granted was $16.37 and $15.19 per share for thenine months ended* September 30, 2026and2025,* respectively.

Restricted Stock Units (RSUs)

A summary of restricted stock unit activity for thenine months ended* September**30,* 2026 is as follows:

Stock-Based Compensation Expense

Total stock-based compensation expense in the condensed consolidated statements of operations is as follows (in thousands):

20

As of* September 30, 2026,*not all of the performance conditions of the performance-based stock awards and the market-based and performance-based stock awards are probable to be achieved. Stock-based compensation expense has only been recognized for those conditions that are assumed to be probable.

Total stock-based compensation expense by award type is as follows (in thousands):

As of* September 30, 2026,*the total unrecognized stock-based compensation expense and the weighted-average period in which the expense is expected to be recognized were as follows:

The fair value of service-based stock options granted and the shares available for purchase under the ESPP were determined using the Black-Scholes option pricing model on the grant date and modification date. The Company estimated the fair value of market-based stock options and both market and performance-based stock options using a Monte Carlo simulation model on the grant date.

The following summarizes the range of assumptions used in calculating the fair value of the awards with stock options grouped by valuation methodology:

21

Note7. Net Loss per Share

The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and warrants converted into common stock are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.

The following outstanding equity instruments were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

Note8. Segment Reporting

The Company conducts business asone operating and reportable segment relating to the research and development of the Company’s NPS technology. The Company’s chief executive officer, who is the chief operating decision maker (“CODM”), views the Company’s operations and manages its business inone operating segment. The CODM uses the Company’s consolidated net loss to monitor actual results as compared to the budget in assessing segment performance and allocation of resources. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CODM uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM is regularly provided with more detailed expense information than what is included in our condensed consolidated statement of operations. All product sales are in the United States and there areno significant groupings of product revenue the CODM considers or reviews when making operating decisions and assessing performance.

To align with the significant expenses provided to the CODM since thesecond quarter of2026, prior period significant expenses have been recast to conform with current period presentation. Previously facilities and IT costs were included within general and administration expenses. Beginning* April 1, 2026,facilities and IT costs are allocated across the significant expense categories based on the allocation methodology used within our GAAP income statement presentation. The recast of prior period information hadno* impact on the Company’s condensed consolidated balance sheets, statements of operations, or statements of cash flows. See Item5 – Other Information for the reclassified presentation of the Company’s prior period segment reporting disclosure.

22

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total net loss in the condensed consolidated statements of operations (in thousands):

1. Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It doesnot include stock-based compensation, depreciation, amortization — see descriptions of Other segment items in footnote7 below.

2. Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.

3. R&D manufacturing and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.

4. Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.

5. General and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal, and human resources.

6. Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company’s products.

*7. *Other segment items includes stock-based compensation, depreciation and amortization.

As of* September 30, 2026and December 31, 2025,*all of the Company’s long-lived assets are located in the United States.

Note9. Related Party Transactions

In* May 2026,the Company’s Board of Directors approved resolutions permitting sales of common stock to its affiliates under the February 2026ATM. Separately, Robert W. Duggan, the Company’s majority stockholder and Co-Chairman of the Company, and Mr. Paul LaViolette, the Chief Executive Officer and Co-Chairman of the Company, indicated their intent to purchase shares at prevailing market prices, subject tono* binding commitments.

In* May 2026,Mr. Duggan and Mr. LaViolette purchased an aggregate of 675,233 shares of common stock under the February 2026ATM at the prevailing market price of $19.69 per share, with Mr. Duggan purchasing 660,233 shares and Mr. LaViolette purchasing 15,000 shares. See Note5* – Stockholders’ Equity for further details on the Company’s ATM sales.

**Note10. **Subsequent Events

Subsequent to* September 30, 2026,the Company sold 192,752 shares of common stock for net proceeds of $10.3 million under the September**2026* ATM.

23